Paper Details

  1. Home
  2. Paper Details

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Author: , CaroJ Jaime, GetsiosDenis, IshakKhajak J, Migliaccio-WalleKristen, O'BrienJudith A, PapadopoulosGeorge

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Alzheimer's disease (AD) affects up to 11% of people over 65 in the United States, and is expected to affect more people as the population ages. AD causes a significant social and economic burden, with the cost of care increasing as the disease progresses.
Paper Details　
Original Abstract of the Article :
Alzheimer's disease (AD) is estimated to affect up to 11% of those aged > or =65 years in the United States, and the number of patients with AD is predicted to increase over the next few decades as the population ages. The substantial social and economic burden associated with AD is well established...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(03)80171-6

データ提供：米国国立医学図書館（NLM）

Galantamine: A Potential Solution for Alzheimer's Disease

Alzheimer's disease (AD), a progressive neurodegenerative disorder, poses a significant challenge to individuals and healthcare systems worldwide. This research delves into the potential of galantamine, a medication used to treat mild to moderate AD, as a solution to the growing burden of this disease. The study examines the economic implications of galantamine treatment, considering its potential impact on healthcare costs associated with managing AD.

Galantamine: A Potential Economic Advantage in Alzheimer's Disease Management

The study suggests that galantamine may offer economic benefits by reducing the overall cost of managing AD. This is a glimmer of hope in the desert of healthcare costs associated with this debilitating condition.

Galantamine: A Potential Tool in the Fight Against Alzheimer's Disease

Just as a resourceful traveler finds a valuable oasis in the desert, galantamine offers a potential tool for mitigating the impact of Alzheimer's disease. This research, like a map guiding us through the complexities of AD management, provides valuable insights into the potential benefits of galantamine treatment.

Dr.Camel's Conclusion

Galantamine, a potential ally in the fight against Alzheimer's disease, offers hope not only for patients seeking relief from cognitive decline but also for healthcare systems grappling with the economic burden of this condition.

Date :
  1. Date Completed 2003-10-30
  2. Date Revised 2019-09-22
Further Info :

Pubmed ID

12860500

DOI: Digital Object Identifier

10.1016/s0149-2918(03)80171-6

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.